New Research Lends Evidence to Risperdal Gynecomastia Claims, May Prove Link to Male Breast Growth

Published on March 18, 2014 by Sandy Liebhard

Text-Size:A A A+


A study led by researchers at the University of British Columbia may have confirmed the link between a widely-used atypical antipsychotic and gynecomastia, a condition alleged in dozens of Risperdal lawsuit filings.

According to findings presented at an American Association for Geriatric Psychiatry (AAGP) meeting on March 15, 2014, data from a large health claims database showed individuals taking the Johnson & Johnson medication as having an increased risk for male breast growth complications in comparison to non-users. Tens of thousands of subjects were included in the research, which also showed men taking Invega, another antipsychotic also distributed by the Johnson & Johnson subsidiary, Janssen Pharmaceuticals Inc., as being 69% more likely to suffer gynecomastia.

Zyprexa users were shown to be 40 percent more likely than non-antipsychotic users to experience this complication, while those taking Seroquel were shown to be at a 41 percent increased risk. Risperdal gynecomastia findings have not yet been published, according to reports.

Risperdal Gynecomastia Allegations Mount in Pennsylvania State Court

When these findings are officially released, one might wonder how they will affect cases now pending in a consolidated Pennsylvania litigation. Court records show more than 200 cases over the medication, which is approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar disorder in adults and adolescents, now filed in the Pennsylvania Court of Common Pleas. Plaintiffs in these cases allege that Johnson & Johnson and Janssen failed to adequately warn about side effects associated with Risperdal, which may include gynecomastia.

This complication may result in liposuction, mastectomy or another surgical procedure to remove excess breast tissue, according to claims.

Product liability lawsuits are not the only legal battle Johnson & Johnson have recently been involved in, however. In a historic settlement with the U.S. Department of Justice, the company paid $2.2 billion to resolve claims involving its marketing of Risperdal and certain other medications that may have been promoted for uses not approved by the FDA.  Children may have been prescribed Risperdal before it was approved for pediatric uses, according to the federal government, as were elderly patients with dementia.

Contact a Risperdal Lawyer Today

Call our Firm to find out more about Risperdal lawsuits, and whether you may be eligible to file a claim alleging gynecomastia. Attorneys can be reached directly at .